Structure via PubChem · Public domain (PubChem)
rimegepant
Sign in to saveAlso known as BHV-3000, BMS-927711
Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic treatment of episodic migraine in adults. It is taken by mouth to dissolve on or under the tongue. It works by blocking CGRP receptors.
Key facts
- Drug.image
- Rimegepant.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Nurtec ODT, Vydura
- Drug.MedlinePlus
- a620031
- Drug.DailyMedID
- Rimegepant
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- By mouth
- Drug.class
- Calcitonin gene-related peptide receptor antagonist
- Drug.ATC_prefix
- N02
- Drug.ATC_suffix
- CD06
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 1289023-67-1
- Drug.PubChem
- 51049968
- Drug.DrugBank
- DB12457
via Wikipedia infobox
Chemical data
- Formula
- C28H28F2N6O3
- Molecular weight
- 534.6 g/mol
- IUPAC name
- [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
- SMILES
- C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
- InChIKey
- KRNAOFGYEFKHPB-ANJVHQHFSA-N
- XLogP
- 2.3
- Polar surface area
- 114 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- trigeminal neuralgia, psoriasis, pain, temporomandibular joint disorder
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 534.219
Show 4 more facts
- canonical SMILES
- C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
- chemical formula
- C₂₈H₂₈F₂N₆O₃
- isomeric SMILES
- C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
- subject has role
- calcitonin gene-related peptide receptor antagonist
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Mechanism of action
- History
- Society and culture
- Legal status
- Economics
- References
- External links
Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic treatment of episodic migraine in adults. It is taken by mouth to dissolve on or under the tongue. It works by blocking CGRP receptors.
In the United States, rimegepant was approved for treating acute migraine in February 2020, and its approval was extended to preventing episodic migraine in June 2021. It is produced and marketed by Pfizer. In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel. It was approved for medical use in Canada in December 2023. In the United Kingdom, rimegepant is approved by NICE for the prophylaxis and treatment of acute migraine in adults. In 2023, it was the 206th most commonly prescribed medication in the United States, with more than 2million prescriptions .
Excerpted from Wikipedia’s “rimegepant” article, available under the CC BY-SA 4.0 licence.